As collagen production naturally declines with age, the products that once maintained your results may no longer be enough to support what your skin needs today
46 Curcumin also reduces inflammatory processes in cardiovascular disease, pulmonary disease, 47 allergies, pancreatitis, psoriasis, atherosclerosis, and chronic anterior uveitis as well as certain types of cancer
So if retatrutides phase 3 trials finish in 2025 or early 2026, approval and market availability by late 2026 or 2027 is a plausible target assuming all goes well
What distinguishes Retatrutide from dual agonists like tirzepatide
These data are further in agreement with our observation in vivo showing that GIPR antagonism, unlike GIPR agonism 15,18 , depends on functional GLP-1R signalling to decrease body weight and food intake (Fig